FDA’s Pepaxto Decider: Peter Marks To Handle Oncopeptides’ Appeal Of Accelerated Approval Withdrawal

 
• By Sue Sutter
peter marks the decider
CBER Director Peter Marks has been delegated the authority to decide if Pepaxto should remain on the market. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock, FDA images

More from Review Pathways

More from Pathways & Standards